Information Provided By: 
Fly News Breaks for November 19, 2019
PGNY
Nov 19, 2019 | 06:23 EDT
Citi analyst Stephanie Demko initiated coverage of Progyny with a Buy rating and $30 price target. The company operates as a pure-play fertility benefits outsourcer for self-insured employers, differentiating itself from peers through a combination of better outcomes, lower cost, and a premium concierge medicine experience, Demko tells investors in a research note. The analyst sees the company as well positioned to benefit from secular trends.
News For PGNY From the Last 2 Days
There are no results for your query PGNY
